secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001404644-24-000085
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene Q2 net loss $18.5M; NGN-401 gets RMAT and START FDA designations
--------------------------------------------------------------------------

- Cash and equivalents $153.9M as of June 30, 2024; expected to fund operations into 2H 2026.
- Net loss $18.5M in Q2 2024 vs $11.9M in Q2 2023; R&D expenses rose to $15.7M from $10.3M.
- NGN-401 for Rett syndrome received RMAT designation and was selected for FDA START Pilot Program.
- First patient dosed in high-dose Cohort 2; interim efficacy data from Cohort 1 expected Q4 2024.
- Enrollment complete in NGN-101 for CLN5 Batten disease; data and regulatory update in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000085/0001404644-24-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000085/ngne-20240809.htm
  HTML page:      https://secwatch.observer/filing/0001404644-24-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer